Fundz

Artiva Biotherapeutics, Inc. reported raising $120 Million in an initial SEC Form D filing, from an offering of $120 Million

PUBLIC · ARTVApr 05, 2021

Amount Raised

$120 Million

$120 Million sold, per SEC Form D (first sale Apr 5, 2021)

Round Type

Venture

San DiegoBiotechnologyHealth CareTherapeutics

Quick answer

Artiva Biotherapeutics raised $120 Million in a funding round, dated April 5, 2021. Artiva Biotherapeutics is based in San Diego, California, United States.

How much did Artiva Biotherapeutics raise?
Artiva Biotherapeutics raised $120 Million in a funding round on April 5, 2021.
What does Artiva Biotherapeutics do?
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.
Where is Artiva Biotherapeutics based and how big is it?
Artiva Biotherapeutics is based in San Diego, California, United States. Fundz records about 95 employees.
Who are the decision-makers at Artiva Biotherapeutics?
Fundz holds 1 contact at Artiva Biotherapeutics. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Artiva Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Numab Therapeutics raised an undisclosed amount (Series C) on May 20, 2021.
  • Immunome Inc. raised an undisclosed amount (Grant) on May 20, 2021.
  • MAIA Biotechnology raised $8M (Funding Round) on May 19, 2021.
  • Eikon Therapeutics raised $103M on May 13, 2021.
  • Nuvalent raised $135M on May 12, 2021.
  • Nuvalent raised $135M (Series B) on May 11, 2021.

Who to call at Artiva Biotherapeutics, and when

A new round usually means Artiva Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Artiva Biotherapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Artiva Biotherapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Artiva Biotherapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Artiva Biotherapeutics

Location

San Diego, California, United States

About

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Artiva Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts21 people are listed at Artiva Biotherapeutics. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Artiva Biotherapeutics's next move

See what Strategic adds

Artiva Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.